GB201913603D0 - New compounds - Google Patents

New compounds

Info

Publication number
GB201913603D0
GB201913603D0 GB201913603A GB201913603A GB201913603D0 GB 201913603 D0 GB201913603 D0 GB 201913603D0 GB 201913603 A GB201913603 A GB 201913603A GB 201913603 A GB201913603 A GB 201913603A GB 201913603 D0 GB201913603 D0 GB 201913603D0
Authority
GB
United Kingdom
Prior art keywords
new compounds
compounds
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201913603A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vicore Pharma AB
Original Assignee
Vicore Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma AB filed Critical Vicore Pharma AB
Priority to GB201913603A priority Critical patent/GB201913603D0/en
Publication of GB201913603D0 publication Critical patent/GB201913603D0/en
Priority to PCT/GB2020/052261 priority patent/WO2021053344A1/en
Priority to CA3152218A priority patent/CA3152218A1/en
Priority to US17/761,670 priority patent/US12435072B2/en
Priority to AU2020351301A priority patent/AU2020351301B2/en
Priority to CN202080065335.5A priority patent/CN114786774A/zh
Priority to EP20780297.6A priority patent/EP4031240A1/en
Priority to JP2022516299A priority patent/JP7771049B2/ja
Priority to KR1020227008929A priority patent/KR20220101071A/ko
Priority to PH1/2022/550564A priority patent/PH12022550564A1/en
Priority to MX2022003286A priority patent/MX2022003286A/es
Priority to BR112022003130A priority patent/BR112022003130A2/pt
Priority to IL291172A priority patent/IL291172A/en
Priority to CONC2022/0003091A priority patent/CO2022003091A2/es
Priority to MX2025000262A priority patent/MX2025000262A/es
Priority to CL2022000656A priority patent/CL2022000656A1/es
Priority to US19/348,124 priority patent/US20260028333A1/en
Priority to JP2025186669A priority patent/JP2026041728A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB201913603A 2019-09-20 2019-09-20 New compounds Ceased GB201913603D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GB201913603A GB201913603D0 (en) 2019-09-20 2019-09-20 New compounds
BR112022003130A BR112022003130A2 (pt) 2019-09-20 2020-09-18 Compostos inovadores
KR1020227008929A KR20220101071A (ko) 2019-09-20 2020-09-18 새로운 화합물
MX2022003286A MX2022003286A (es) 2019-09-20 2020-09-18 Nuevos compuestos.
US17/761,670 US12435072B2 (en) 2019-09-20 2020-09-18 Compounds
AU2020351301A AU2020351301B2 (en) 2019-09-20 2020-09-18 New compounds
CN202080065335.5A CN114786774A (zh) 2019-09-20 2020-09-18 新化合物
EP20780297.6A EP4031240A1 (en) 2019-09-20 2020-09-18 New compounds
JP2022516299A JP7771049B2 (ja) 2019-09-20 2020-09-18 新化合物
PCT/GB2020/052261 WO2021053344A1 (en) 2019-09-20 2020-09-18 New compounds
PH1/2022/550564A PH12022550564A1 (en) 2019-09-20 2020-09-18 New compounds
CA3152218A CA3152218A1 (en) 2019-09-20 2020-09-18 New compounds
IL291172A IL291172A (en) 2019-09-20 2022-03-07 new compounds
CONC2022/0003091A CO2022003091A2 (es) 2019-09-20 2022-03-17 Nuevos compuestos
MX2025000262A MX2025000262A (es) 2019-09-20 2022-03-17 Nuevos compuestos
CL2022000656A CL2022000656A1 (es) 2019-09-20 2022-03-17 Nuevos compuestos
US19/348,124 US20260028333A1 (en) 2019-09-20 2025-10-02 New compounds
JP2025186669A JP2026041728A (ja) 2019-09-20 2025-11-05 新化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201913603A GB201913603D0 (en) 2019-09-20 2019-09-20 New compounds

Publications (1)

Publication Number Publication Date
GB201913603D0 true GB201913603D0 (en) 2019-11-06

Family

ID=68425648

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201913603A Ceased GB201913603D0 (en) 2019-09-20 2019-09-20 New compounds

Country Status (15)

Country Link
US (2) US12435072B2 (https=)
EP (1) EP4031240A1 (https=)
JP (2) JP7771049B2 (https=)
KR (1) KR20220101071A (https=)
CN (1) CN114786774A (https=)
AU (1) AU2020351301B2 (https=)
BR (1) BR112022003130A2 (https=)
CA (1) CA3152218A1 (https=)
CL (1) CL2022000656A1 (https=)
CO (1) CO2022003091A2 (https=)
GB (1) GB201913603D0 (https=)
IL (1) IL291172A (https=)
MX (2) MX2022003286A (https=)
PH (1) PH12022550564A1 (https=)
WO (1) WO2021053344A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202013721D0 (en) * 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
GB202104033D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds
EP4313953A1 (en) * 2021-03-23 2024-02-07 Vicore Pharma AB Selective angiotensin ii receptor ligands
GB202113583D0 (en) * 2021-09-23 2021-11-10 Vicore Pharma Ab New compounds
GB202104038D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
MX2024000518A (es) * 2021-07-09 2024-01-31 Vicore Pharma Ab Nuevos compuestos selectivos de angiotensina ii.
CA3247073A1 (en) * 2022-04-06 2025-02-03 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company AT2R AGONIST
IE20230600A3 (en) 2022-12-22 2025-09-24 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease
WO2024149712A1 (en) * 2023-01-09 2024-07-18 Vicore Pharma Ab Selective angiotensin ii compounds
CN119504723A (zh) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 作为at2r激动剂的噻吩磺酰基氨基甲酸酯
WO2025146172A1 (zh) * 2024-01-03 2025-07-10 武汉人福创新药物研发中心有限公司 一种并环类化合物作为at2r激动剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
YU78601A (sh) 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
DE19920815A1 (de) 1999-05-05 2000-11-09 Aventis Pharma Gmbh 1-(p-Thienylbenzyl)-Imidazole als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100938817B1 (ko) 2001-05-31 2010-01-26 바이코어 파마 아베 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물
CA2449150C (en) 2001-05-31 2011-07-12 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists
WO2004046141A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
AU2006235698B2 (en) 2005-04-12 2012-03-29 Vicore Pharma Ab New tricyclic angiotensin II agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
KR20150028761A (ko) * 2011-12-16 2015-03-16 타릭스 파마슈티컬스 엘티디. 섬유증 치료용 안지오텐신
KR102230461B1 (ko) 2013-03-15 2021-03-22 유니버시티 오브 써던 캘리포니아 엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들
EP2832357A1 (en) 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selective AT2 receptor agonists for use in treatment of cachexia
BR112017012337A2 (pt) 2014-12-12 2018-02-27 Vicore Pharma Ab Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação.
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
CN107405406A (zh) * 2015-03-02 2017-11-28 维科尔药物公司 用于治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
AR108906A1 (es) * 2016-06-29 2018-10-10 Bristol Myers Squibb Co Heterociclos de biarilmetilo
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy

Also Published As

Publication number Publication date
AU2020351301A1 (en) 2022-03-17
EP4031240A1 (en) 2022-07-27
JP2022549086A (ja) 2022-11-24
AU2020351301B2 (en) 2026-02-12
JP7771049B2 (ja) 2025-11-17
IL291172A (en) 2022-05-01
CN114786774A (zh) 2022-07-22
BR112022003130A2 (pt) 2022-05-17
CL2022000656A1 (es) 2022-11-04
US20260028333A1 (en) 2026-01-29
KR20220101071A (ko) 2022-07-19
PH12022550564A1 (en) 2023-03-20
US20220388994A1 (en) 2022-12-08
US12435072B2 (en) 2025-10-07
CA3152218A1 (en) 2021-03-25
MX2022003286A (es) 2022-04-12
CO2022003091A2 (es) 2022-04-19
WO2021053344A1 (en) 2021-03-25
MX2025000262A (es) 2025-02-10
JP2026041728A (ja) 2026-03-10

Similar Documents

Publication Publication Date Title
IL289463A (en) Agonist-gipr compounds
IL291172A (en) new compounds
GB201905721D0 (en) Compounds
GB201910305D0 (en) Compounds
GB201916915D0 (en) Compounds
GB201912404D0 (en) New compounds
GB201908536D0 (en) Compounds
GB201910304D0 (en) Compounds
GB201908171D0 (en) Compounds
GB201908095D0 (en) Carboxy-MIDA-boronate compounds
GB201915318D0 (en) New compounds
GB201911942D0 (en) New compounds
GB201908147D0 (en) New compounds
GB201919205D0 (en) Compounds
GB201918761D0 (en) Compounds
GB201918424D0 (en) Compounds
GB201917895D0 (en) Compounds
GB201917893D0 (en) Compounds
GB201901862D0 (en) New compounds
GB201901861D0 (en) New compounds
GB201901854D0 (en) New compounds
GB201901860D0 (en) New compounds
GB201901859D0 (en) New compounds
GB201901858D0 (en) New compounds
GB201901857D0 (en) New compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)